glp-1 news past 2 days Weight-loss drugs such as Ozempic were in the headlines a lot in 2025 – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ GLP-1RA Cuts Cardiovascular and Poor Appetites Flavor:The Smooth Operator

glp-1 news past 2 days Weight-loss drugs such as Ozempic were in the headlines a lot in 2025 – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ GLP-1RA Cuts Cardiovascular and Poor Appetites Flavor:The Smooth Operator

GLP-1RA Cuts Cardiovascular and Kidney Risk in Lupus - EMJ

Unlike oral semaglutide (Rybelsus

Poor Appetites

Flavor:The Smooth Operator

This approval makes Eli Lilly’s oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug for weight loss available in pill form, after Wegovy, which gained approval in December 2025